欧洲血友病及相关疾病协会、欧洲血友病联盟、国际血栓与止血学会及世界血友病联盟关于先天性出血性疾病患者肝病管理的指南
先天性出血性疾病患者因替代治疗曾面临慢性病毒性肝炎和肝硬化风险,新型止血药物及有效抗病毒治疗已显著降低该风险。肝病严重程度及代谢功能障碍、酒精等慢性肝损伤因素仍影响肝脏健康。多学科专家基于最新诊疗方案制定本实践性多学会指南,保护肝脏健康并防治肝并发症。
要点
- 先天性出血性疾病患者曾因替代治疗面临慢性病毒性肝炎和肝硬化风险。
- 新型止血策略及有效抗乙肝、丙肝病毒治疗已显著降低该风险。
- 肝病严重程度及代谢功能障碍、酒精等慢性肝损伤因素可导致肝细胞癌、门脉高压和肝功能不全等残留风险。
核心结论
- 多学会专家制定本实践性指南,旨在保护先天性出血性疾病患者肝脏健康并防治肝并发症。
研究设计与样本
- 由肝病学家、血液学家、先天性出血性疾病治疗医师及患者代表组成的专家组,基于最新诊疗方案制定多学会实践性指南。
主要发现
- 先天性出血性疾病患者接受替代治疗后曾面临慢性病毒性肝炎和肝硬化风险。
- 新型止血药物策略及有效抗丙型肝炎病毒和乙型肝炎病毒治疗已显著降低该风险。
- 肝脏健康的最终成功还受抗病毒治疗时肝病严重程度及代谢功能障碍和/或酒精等慢性肝损伤因素暴露影响。
- 上述因素可导致肝细胞癌、门脉高压和肝功能不全等残留并发症风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
People with bleeding disorders (PWBD) have been exposed to the risk of developing chronic viral hepatitis and cirrhosis after replacement therapy. Today, the advent of new pharmacologic strategies for the control of hemostasis and the efficacious antiviral therapies against hepatitis C virus and hepatitis B virus have significantly reduced this risk. However, the definitive success for liver health in this clinical setting is also influenced by other factors, such as the severity of liver disease at the time of hepatitis B virus/hepatitis C virus antiviral therapy and the exposure to highly prevalent factors of chronic liver damage (eg, metabolic dysfunction and/or alcohol) that can cause a residual risk of complications such as hepatocellular carcinoma, portal hypertension, and liver insufficiency. With this background, a group of experts selected among hepatologists, hematologists, PWBD treaters, and patient representatives produced this practical multisociety guidance for the protection of liver health and the prevention and management of liver complications in PWBD based on the most updated protocols of care.
引用
- La Mura V, Colombo M, Foster GR, et al. The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of Hemophilia. J Thromb Haemost. 2024. PMID: 39271019. doi:10.1016/j.jtha.2024.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。